Compare PRTA & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | IDR |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.4M | 509.9M |
| IPO Year | 2013 | 2000 |
| Metric | PRTA | IDR |
|---|---|---|
| Price | $8.36 | $28.76 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 307.4K | 189.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 70.15 |
| EPS | 0.26 | ★ 0.63 |
| Revenue | $814,000.00 | ★ $42,406,253.00 |
| Revenue This Year | $1,111.38 | $25.52 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $34.35 | $49.06 |
| Revenue Growth | N/A | ★ 64.59 |
| 52 Week Low | $7.73 | $26.02 |
| 52 Week High | $11.80 | $54.70 |
| Indicator | PRTA | IDR |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 39.45 |
| Support Level | $8.62 | $28.95 |
| Resistance Level | $9.36 | $35.52 |
| Average True Range (ATR) | 0.33 | 1.41 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 8.60 | 2.93 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.